10.09.2017 - Nivolumab Plus Ipilimumab Demonstrated Superior Overall Survival and Showed Durable Responses

10.09.2017 - Pressemitteilung der Bristol-Myers Squibb GmbH & Co. KGaA 
Nivolumab plus Ipilimumab reduced the risk of death by 37% versus standard of care, Sunitinib, in intermediate- and poor-risk patients. The combination also significantly improved overall survival in all randomized patients.  

Aktualisiert am: 24.09.2018 17:42